Diazon Pharmaceuticals |
2
home,page,page-id-2,page-template,page-template-full_width,page-template-full_width-php,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-10.0,wpb-js-composer js-comp-ver-4.12,vc_responsive

ABOUT DIAZON PHARMACEUTICALS

Embedded in its novel mechanism of action, Diazon’s new generation onco-therapeutic DZ-2384 targets a proven therapeutic pathway in oncology, but one whose potential in modern cancer therapy has been severely restricted due to unacceptable toxicities. DZ-2384 overcomes this restriction by modulating microtubule structure and dynamics in a distinct way, delivering potent anti-tumor efficacy with an unusually superior safety profile, including lack of neurotoxicity in preclinical models – qualities that are widely sought by clinicians. In addition to replacing the current drugs that target microtubules, Diazon believes that DZ-2384 has the potential to safely combine with targeted therapeutics, including immunotherapies.

| DISTINCT MECHANISM

DZ-2384 exhibits a unique binding mode to tubulin which imparts distinct effects on anti-tumor efficacy and superior safety margins compared to other MTAs.

| WITHOUT NEUROTOXICITY

An important distinction of DZ-2384 is the absence of peripheral neuropathy in a rat model throughout the efficacious dose range.

| HIGHLY EFFICACIOUS

DZ-2384 exhibits potent anti-tumor activity both as a single agent and in combination in xenograft, patient-derived xenograft, and genetically engineered mouse models.